Company: NDRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001654954-25-009643
Chunk: 16

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
 Stock Common Stock Options Stock options are awarded to the Company’s employees, consultants and non-employee members of the board of directors under the Omnibus Plan and are generally granted with an exercise price equal to the market price of the Company’s common stock at the date of grant. There were no issuances of stock options in the quarter ended June 30, 2025. A summary of option activity under the Company’s Omnibus Plan as of June 30, 2025, and changes during the quarter then ended, is presented below:       Weighted     Weighted  Average     Average  Remaining   Number of  Exercise  Contractual   Options  Price  Term (Years) Balance outstanding at December 31, 2024  278  $30,628.90   5.35 Granted  -   -   - Exercised  -   -   - Forfeited  -   -   - Cancelled or expired  (12)  120,055.83   - Balance outstanding at June 30, 2025  266  $26,594.61   5.05 Exercisable at June 30, 2025  228  $29,809.64   4.63 

 12Table of Contents

 Restricted Stock Units      On June 11, 2025, the Company granted a total of 161,527 restricted stock units ("RSUs") under its Omnibus Plan. The fair value per share (closing stock price) was $3.37.  The grants included both standard RSUs issued to members of the Board of Directors and performance-based RSUs ("PBRSUs") issued to employees. The PBRSUs are subject to both service and performance vesting conditions. During the three months ended June 30, 2025, the Company recognized $39,530 in stock-based compensation expense related to these RSU and PBRSU grants. This expense is included in total operating expenses in the condensed consolidated statements of operations. Unrecognized stock-based compensation expense related to these RSUs will be recognized over the remaining vesting period, which is one year for standard RSUs and subject to performance conditions for PBRSUs. As of June 30, 2025, the total compensation expense to be recognized in future